We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




P-O-C Assay Detects Respiratory Syncytial Virus in Older Adults

By LabMedica International staff writers
Posted on 22 Feb 2022
Print article
Image: The Xpert Xpress Flu/RSV Assay is intended as an aid in the diagnosis of influenza and respiratory syncytial virus infections (Photo courtesy of Cepheid)
Image: The Xpert Xpress Flu/RSV Assay is intended as an aid in the diagnosis of influenza and respiratory syncytial virus infections (Photo courtesy of Cepheid)

The point-of-care Xpert Xpress Flu/RSV test appeared nearly as accurate as routine real-time RT-PCR for detecting respiratory syncytial virus (RSV) infections in older adults, a Dutch study found.

Lower respiratory tract infections are estimated to be the fifth-leading cause of mortality worldwide. Respiratory syncytial virus (RSV) is a major cause of respiratory infections in older adults (≥60 years) with a substantial disease burden.

Currently, the gold standard for RSV diagnosis is laboratory-based real-time reverse-transcription polymerase chain reaction (RT-PCR). RT-PCR has the disadvantage that it requires technical skills and has a long turnaround time. Therefore, reliable rapid diagnostic tests are needed to improve patient management, to enable cohorting and isolation of hospitalized patients, to prevent unnecessary use of antibiotics.

Pediatric Immunology and Infectious Disease Specialists at the University Medical Centre Utrecht (Utrecht, The Netherlands) and their international colleagues collected 758 respiratory samples from 561 older adults at a median of 4 days after symptom onset, from two consecutive RSV seasons. Participants were recruited from 17 general practices before the start of each RSV season. A little more than half of participants were women (54%), the median age was 75, and about 38% had comorbidities Two nasopharyngeal minitip flocked swabs (FLOQSwab, Copan Diagnostics, Brescia, Italy) were collected by a member of the study team and directly stored in universal transport medium.

The team compared the performance of the Xpert® Xpress Flu/RSV assay (Cepheid, Sunnyvale, CA, USA) with real-time reverse-transcription polymerase chain reaction (RT-PCR) in the home-dwelling older adults. For the Xpert Xpress Flu/RSV assay, the cartridge was opened and the entire content of the filled pipette was slowly expelled into the cartridge. Subsequently, the cartridge was inserted into the GeneXpert System. After approximately 30 minutes, test results were available on the screen. For RT-PCR, an in-house–developed kit was used. RSV-A and -B were detected and quantified by duplex RT-PCR using specific amplification primers and fluorescent probes designed to detect the RSV N gene.

The scientists reported that 35 (4.6%) samples tested positive for RSV by at least one of the assays, of which two samples were negative by Xpert Xpress Flu/RSV and three samples by real-time RT-PCR. The positive percentage agreement (PPA) was 90.9% (95% confidence interval [CI], 76.4%–96.8%) and negative percentage agreement was 99.7% (95% CI, 99.0%–99.9%). Viral loads were low (≤103 copies/mL or cycle threshold value ≥34) in all cases with discordant results for the two assays.

The authors concluded that they had performed the first international prospective community-based study to compare the performance of a rapid molecular detection test for RSV infection with RT-PCR in home-dwelling older adults. They demonstrated that the PPA and overall rate of agreement between Xpert Xpress Flu/RSV and routine RSV RT-PCR for RSV detection in home-dwelling older adults is high. The assay is fast and easy to use and therefore has the ability to improve patient management and outcomes. The study was published on February 4, 2022 in The Journal of Infectious Diseases.

Related Links:
University Medical Centre Utrecht 
Copan Diagnostics
Cepheid 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.